-
New Phase 3 Trial Explores Shorter Treatment Path for Drug-Resistant Tuberculosis
A newly launched Phase 3 trial is testing quabodepistat-containing drug regimens that could shorten treatment for drug-resistant tuberculosis to as little as four months. The study aims to offer patients faster, potentially more tolerable paths to recovery.
-
Arch Biopartners Expands Phase 2 LSALT Peptide Trial to the United States
Arch Biopartners is broadening its ongoing Phase 2 trial of its LSALT peptide to include U.S. study sites, marking a significant step forward in the therapy’s clinical development.
-
New Peptide Probe Shows Promise for Targeted Tumor Imaging
Researchers have developed a CD147-targeting peptide probe designed to improve tumor visualization, with early pilot clinical testing suggesting potential for more precise cancer imaging.
-
FDA-Approved Peptide Therapies Offer New Hope for Weight Management
The FDA continues to approve peptide-based medications for weight loss, giving patients and doctors more evidence-based tools to address obesity and related health conditions.
-
Eli Lilly Extends Compassionate Access to Obesity Medication for Older Patient
Eli Lilly provided expanded access to one of its investigational obesity medications for a 79-year-old patient, highlighting how pharmaceutical companies can offer flexible pathways to emerging treatments.
-
FDA Advisory Committee Signals Support for Expanded Access Pathway for BPC-157 and KPV
An FDA advisory committee has voted in favor of a pathway that could expand access to the peptides BPC-157 and KPV, a development welcomed by industry voices as a step toward more structured regulatory clarity.
-
FDA Advisory Panel to Explore Expanding Access to Certain Peptides
The FDA is convening a panel to discuss potentially broadening access to select peptide therapies, a move that could open new doors for patients and researchers alike.
-
First-in-Class Parkinson’s Peptide TT-P34 Clears Phase I Trial with Encouraging Results
Teitur Trophics has reported successful Phase I clinical trial results for TT-P34, a novel peptide therapy designed to target underlying mechanisms of Parkinson’s disease. The milestone marks an encouraging step forward for a first-in-class approach to the condition.
-
Therapeutic Peptides: A Growing Toolkit for Modern Medicine
A new review highlights how therapeutic peptides are expanding across medicine, from established treatments to promising next-generation designs. The article underscores the field’s rapid growth and bright outlook for future drug development.
-
Peptide Therapy: A Promising Frontier in Targeted Medicine
Peptide-based therapies are gaining attention for their ability to precisely target biological pathways, offering new possibilities for treating a range of health conditions with fewer side effects than traditional drugs.